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Chronic kidney disease (CKD) has been known to be associated with an increased risk of cardiovascular (CV) mortality
and morbidity in Japan. Although traditional risk factors contribute to the development of CV disease in CKD patients,
they cannot fully explain the unacceptably high incidence of CV mortality. Recently, non-traditional risk factors, including
abnormal mineral metabolism, have been suggested to be involved in the increased risk of CV events. The medical
treatment of CKD-mineral bone disorders (CKD-MBD) has been associated with encouraging, but inconsistent,
improvement in CV disease complications and patient survival. A better understanding of the biomarkers and
mechanisms involved in left ventricular hypertrophy (LVH) and vascular calcification might improve the diagnosis
and treatment of the CV disease secondary to CKD-MBD, thus improving patient survival. Recent insights into
fibroblast growth factor 23 (FGF23) and its co-receptor, Klotho, have led to marked advancements in the interpretation
of data about CKD-MBD and CV damage.
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Japan is one of the countries with the highest incidence
of end-stage renal disease (ESRD) globally, and the number
of Japanese patients with ESRD is continuously increasing
[1]. Chronic kidney disease (CKD) is known to be associated
with an increased risk for cardiovascular (CV) mortality
and morbidity in Japan [2]. CV diseases account for
30–50% of all-cause mortality in CKD patients, especially
dialysis patients worldwide [1, 3]. Although traditional risk
factors contribute to the development of CV disease in
CKD patients, they cannot fully explain the unacceptably
high incidence of CV mortality in these patients. Hence,
non-traditional risk factors, including abnormal mineral
metabolism, are thought to be involved in the increased
risk of CV events [4, 5].
There is growing interest in the issues surrounding
CKD-mineral and bone disorder (CKD-MBD) [6]. CKD
has been shown to be associated with bone and mineral
disorder characterized by (i) laboratory abnormalities of
calcium, phosphate, parathyroid hormone (PTH), andCorrespondence: knitta@twmu.ac.jp
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calcification. Vascular calcification is associated with adverse
clinical outcomes, including ischemic CV events and subse-
quent vascular mortality [7]. The pathogenesis of vascular
calcification in CKD is complex, and rather than being
attributable to a simple process of calcium and phos-
phate precipitation, involves an active process where
vascular smooth muscle cells (VSMCs) undergo apoptosis
with release of matrix vesicles and are transformed into
osteoblast-like cells [7].
The complex mechanisms by which aging leads to in-
creased vascular calcification remain uncertain. However,
there is no doubt that patients with ESRD are at high risk
of and have a high prevalence of vascular calcification be-
cause of multiple risk factors that induce the phenotypic
transformation of VSMCs into osteoblast-like cells capable
of carrying out tissue mineralization [8]. Vascular calcifica-
tion has been associated with numerous traditional CV
risk factors, including advanced age, hypertension, dia-
betes, and dyslipidemia, as well as with non-traditional
CV risk factors, including hyperphosphatemia, hyperpara-
thyroidism, and excessive calcium intake [9]. There are
two patterns of vascular calcification. One occurs in thele is distributed under the terms of the Creative Commons Attribution 4.0
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the vessel wall as in Mönckeberg’s sclerosis, which is very
common in ESRD patients. The hemodynamic conse-
quences of vascular calcification include loss of arterial
elasticity, an increase in pulse wave velocity, left ventricu-
lar hypertrophy, a decrease in coronary artery perfusion,
and myocardial ischemia (Fig. 1).
Recent studies have shown that fibroblast growth factor
23 (FGF23), a bone-derived phosphatonin, and its co-
receptor Klotho play an important role in the regulation
of calcium and phosphate metabolism in CKD-MBD [10].
This review summarizes the pathophysiology involving
the FGF23-Klotho axis, with particular focus on the recent
advances elucidating its role in CV disease, which are
characterized by left ventricular hypertrophy (LVH) and
vascular calcification.Mineral metabolism and vascular calcification
As earlier mentioned, numerous risk factors for vascular
calcification have been reported. Traditional risk factors
include advanced age, hypertension, diabetes, and dyslipid-
emia. Non-traditional risk factors in CKD include disorders
of mineral metabolism, elevated serum PTH levels, exces-
sive intake of calcium supplements, inflammation, malnu-
trition, and oxidative stress [11]. Patients with advanced
CKD develop hyperphosphatemia secondary to impaired
renal phosphate excretion. There is strong evidence that
vascular calcification is closely associated with high serum
calcium and phosphate levels. High serum phosphate levels
can be considered a vascular toxin [12], and clinical studies
have shown that patients with the poorest phosphate
control experience the most rapid progression of vascular
calcification [13].Fig. 1 Schematic representation of the clinical effects of arterial intimal andTwo different mechanisms of vascular calcification
have been proposed to explain the relationship between
calcium and phosphate disorders and vascular calcification.
Experimental studies have demonstrated that calcium plays
a role in the development of vascular calcification by
stimulating mineralization of VSMCs under normal phos-
phate conditions [14]. When phosphate levels are elevated,
this calcium-driven mineralization is accelerated syner-
gistically and hyperphosphatemia may directly induce
vascular injury, and it indirectly stimulates osteoblastic
differentiation through a type III sodium-dependent
phosphate co-transporter (PiT-1) [15]. New discoveries
related to extracellular vesicles, microRNAs, and calci-
protein particles (CPPs) further reveal the mechanisms
involved in the initiation and progression of vascular
calcification in CKD [16]. Thus, elevated intracellular
phosphate concentration may directly stimulate VSMCs
to transform into calcifying cells by activating genes asso-
ciated with osteoblastic functions. These findings provide
strong evidence that excess phosphate and calcium load is
probably the most important pathogenic factor in vascular
calcification.
Interaction between FGF23 and Klotho
FGF23 is a 32 kDa protein synthesized primarily in oste-
ocytes, and the corresponding gene encodes a 251-amino-
acid protein, including a 24-amino-acid signal peptide
[17]. FGF23 circulates in two distinct forms, a single,
intact, full-length active protein and a shorter, inactive
protein. Intact-FGF23 activates FGF receptors (FGFRs)
1, 3, and 4 to elicit tissue-specific responses through
the subsequent induction of two main pathways: (1)
Klotho-dependent activation of the mitogen-activated
protein kinase (MAPK) cascade, leading to extracellularmedial calcification. Cited from [7]
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sion, and (2) a Klotho-independent cascade, characterized
by phosphoinositide-specific phospholipase C (PLC) γ-
dependent activation of the calcineurin-nuclear factor
of activated T-cells (NFAT) [18]. FGF23 appears to impair
synthesis and accelerate degradation of 1, 25 (OH)2D.
Recombinant FGF23 also has a phosphaturic effect, which
is attributable to reduced renal phosphate reabsorption.
FGF23 downregulates the expression of both type IIa
and type IIc sodium-phosphate cotransporters on the
apical surface of renal proximal tubular epithelial cells
in vivo [19].
The effects of FGF23 are influenced by Klotho, which
is itself a 130-kDa transmembrane β-glucuronidase that
catalyzes the hydrolysis of steroid β-glucuronides. Klotho
was discovered by Kuro-o et al. in 1997 [20]. The Klotho
gene is expressed in a limited number of tissues, mainly
the kidneys, and mutations cause multiple aging-related
disorders in nearly all organs and tissues. FGF23 exerts
its biological effects through activation of FGFRs in a
Klotho-dependent manner (Fig. 2), because a Klotho/
FGFR complex binds to FGF23 with higher affinity than
FGF-R or Klotho alone [21]. Thus, activation of FGF23
receptors requires not only circulating FGF23, but also the
presence of Klotho as a specific promoter whose affinity
dictates the selectivity towards its targets.
Because of the reduction in functioning nephrons dur-
ing CKD progression, each nephron is required to excrete
an increasing amount of phosphate to maintain normal
serum phosphate levels. This can be attained by increasing
serum FGF23 levels, which is an early sign of changes in
phosphate metabolism during CKD progression. However,Fig. 2 Interaction between FGF23 and Klotho. Cited from [10]because FGF23 is a counter-regulatory hormone for vita-
min D, an increase in its levels is at the expense of vitamin
D synthesis. Decreasing vitamin D in turn stimulates PTH
secretion, leading to secondary hyperparathyroidism. In
fact, decreases in serum 1, 25 (OH)2D levels and increases
in serum PTH levels are observed in patients with
early-stage CKD with normophosphatemia. The fact that
Klotho expression in the parathyroid gland is decreased in
CKD patients may explain why elevated serum FGF23
levels fail to suppress PTH. The increase of FGF23 was
associated with the decrease of 1, 25 (OH)2D in CKD
patients [22]. Moreover, the inhibition of FGF23 activity
in the animal model of CKD increased serum 1, 25 (OH)2D
[23]. While the reduction of 1, 25 (OH)2D by increased
FGF23 is likely to reduce intestinal phosphate absorption
and contribute to maintaining serum phosphate level, it
may induce or aggravate secondary hyperparathyroidism.
However, the role of FGF23 in the development of sec-
ondary hyperparathyroidism is complex because FGF23
was shown to directly inhibit production and secretion
of PTH [24]. With the progression of CKD, the expression
of Klotho in the kidneys and parathyroid glands were
shown to decrease that likely leads to impaired actions of
FGF23 [25].
Elevated serum FGF23 levels and low vitamin D may
further reduce Klotho expression in the kidney and para-
thyroid tissue in CKD patients, because FGF23 and vitamin
D can downregulate and upregulate Klotho expression,
respectively. Decline in Klotho expression exacerbates
FGF23 resistance in the kidney and parathyroid gland,
further increasing FGF23, decreasing vitamin D, and in-
creasing PTH. This vicious cycle (Fig. 3) may contribute
Fig. 3 Changes in phosphate-regulating factors during CKD progression. Cited from [26]
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in CKD patients [26]. In the advanced stages of CKD,
increased FGF23 can no longer compensate for dietary
phosphate overload, resulting in overt hyperphosphatemia,
vitamin D deficiency, and parathyroid hyperplasia. The
fact that patients with advanced stage CKD have extremely
high serum levels of biologically active FGF23 has raised
the possibility that the elevated serum FGF23 levels
may activate FGF signaling in tissues that do not innately
express Klotho, which may then contribute to systemic
complications in ESRD.
It has been reported that calcimimetics decrease plasma
FGF23 concentration in hemodialysis patients, and the
decrease in plasma FGF23 concentration seems to be
related to the decrease in serum phosphate concentra-
tion [27]. Chertow et al. reported the results of the
Evaluation of Cinacalcet Therapy to Lower Cardiovascular
Events (EVOLVE) trial in 3883 patients receiving long-
term hemodialysis treatment [28]. In an unadjusted
intention-to-treat (ITT) analysis, cinacalcet had no signifi-
cant benefit on the primary composite outcome (death or
first non-fatal myocardial infarction, hospitalization for
unstable angina, heart failure, or peripheral vascular
events) but significantly reduced the incidence of heart
failure. In an adjusted ITT analysis and lag-censoring
analysis, the effect of cinacalcet on the primary outcomewas significant. ITT analyses adjusted for baseline char-
acteristics suggest that treating secondary hyperpara-
thyroidism with cinacalcet results in significant reduction
in the risk of death or cardiovascular events.
Role of FGF23 in CV disease
Serum FGF23 levels were independently associated with
left ventricular mass index and the risk of new-onset
LVH in the Chronic Renal Insufficiency Cohort (CRIC)
study [29]. Negishi et al. reported that FGF23 was signifi-
cantly associated with LVH, and they suggested that FGF23
could be a novel biomarker of left ventricular overload,
which is closely associated with an increased risk of death
in hemodialysis patients [30]. We demonstrated that
hemodialysis patients with LVH were more likely to have
higher systolic blood pressure and LVH was significantly
associated with female gender and higher serum phosphate
levels in addition to serum FGF23 levels (Fig. 4) [31].
An experimental study by Faul et al. demonstrated that
FGF23 induced rat cardiomyocyte hypertrophy through
FGFR-dependent activation of the calcineurin-NFAT
signaling pathway in a Klotho-independent manner [32].
FGFR-4 is now considered the specific FGFR directly
involved in the Klotho-independent activity of FGF23 in
the myocardium [33]. FGF23 activates only FGFR-4 in
cardiomyocytes, thereafter stimulating PLC-γ-calineurin-
Fig. 4 Serum fibroblast growth factor 23 (FGF23) level in hemodialysis patients with and without left ventricular hypertrophy (LVH). Cited from [26]
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did not develop LVH in response to high FGF23 levels,
while gain-of-function transgenic mutants of FGFR-4
spontaneously led to LVH [35]. Leifhelt-Nestler et al.
recently reported that FGF23/FGFR4-mediated LVH is
reversible [36]. Moreover, data from 24 deceased patients
with childhood-onset ESRD provides evidence that expres-
sion of FGFR-4 and activation of the PLC-γ-calcineurin-
NFAT pathway were associated with cardiac expression of
FGF23 in situ [36]. Reduced expression of Klotho in the
same cardiac tissues supports the notion that high FGF23
levels concomitant with Klotho downregulation may favor
activation of Klotho-independent pathways that lead to
LVH. Thus, high serum FGF23 levels exert toxic effects via
Klotho-independent pathways in myocardium. However, a
potential effect of LVH on FGF23 remains unclear. Matsui
et al. recently evaluated the effect of LVH on FGF23 using
cardiomyocyte-specific calcineurin A transgenic mice and
showed severe LVH with elevated serum FGF23 levels [37].
The FGF23 levels were elevated in cardio myocytes, but not
osteocytes, suggesting that FGF23 and LVH might be linked
in a vicious cycle, particularly in the setting kidney disease:
LVH itself could increase FGF23, which, in turn, cause
LVH progression.
FGF23 has been associated with abdominal aortic calcifi-
cation in healthy older men [38]. In a study of 545 African
Americans with diabetes, Freedman et al. found an inde-
pendent association of FGF23 with coronary artery-
calcified atherosclerotic plaque, but not with carotid
and aortoiliac-calcified plaque [39]. Among 142 patients
in CKD stages 2 through 5D, intact FGF23 was elevated
and independently associated with aortic calcificationscore, as assessed by multislice, spiral-computed tomog-
raphy (CT) [40]. Morena et al. described a significant
correlation between FGF23 expression and coronary
artery calcification among 195 non-dialysis CKD patients
[41]. Due to the considerable interaction between FGF23
and osteoprotegerin (OPG), these authors suggested that
FGF23 expression represented a biomarker for severe vas-
cular calcification, whereas OPG expression was
associated with moderate coronary calcification [41]. More
recently, Di Lullo et al. demonstrated an independent asso-
ciation between FGF23 expression and the extent of aortic
valve calcification among 100 consecutive non-hospitalized
CKD stage 3–4 patients [42].
Aortic calcification index, which is assessed on non-
contrast CT, was independently associated with serum
levels of intact FGF23 in 65 hemodialysis patients [43].
Although coronary artery and thoracic aortic calcium
concentrations were not associated with serum FGF23
levels among 1501 patients from the CRIC study, sec-
ondary analysis revealed an association between serum
FGF23 levels and thoracic aorta calcium concentrations
among CKD patients with non-zero calcification scores
[44]. This result was statistically significant, despite the
significant association detected between serum phosphate
levels and coronary calcium concentrations. The authors
concluded that these types of studies are highly sensitive
to the specific definition of vascular calcification, the site
of interest, the sample size, and the proportion of subjects
with a calcification score of zero [44].
FGF23 may even be associated with progression of
vascular calcification, although there are discrepancies in
these results. Khan et al. assessed coronary arterial
Nitta Renal Replacement Therapy  (2018) 4:31 Page 6 of 8calcification by electrocardiography-triggered multislice
CT in 99 incident hemodialysis patients [45]. FGF23 was
associated with progression of coronary calcification
independently of serum phosphate levels and known
risk factors [45]. Among 74 hemodialysis patients, pro-
gression of coronary artery calcification, assessed twice
by scoring with a 1-year interval, was associated with
serum levels of FGF23 and phosphate, as well as baseline
coronary calcium scores [46]. Conversely, we reported
higher FGF23 levels in hemodialysis patients with regres-
sion, rather than progression, of aortic arch calcification,
at a 5-year follow-up, as assessed by simple chest radio-
graphs [47].
Prognostic value of FGF23 in CKD patients
Previous studies suggest that elevated serum FGF23 level is
strongly associated with increased mortality risk across the
spectrum of CKD [48–50]. We have recently reported that
serum FGF23 level was not associated with increased mor-
tality risk in our cohort of prevalent hemodialysis patients
[51], suggesting that the impact of FGF23 on mortality may
be modified by gender and previous CV disease and is
blunted by the grade of hyperphosphatemia in ESRD
patients. However, the overall prognostic utility of FGF23
remains unclear. Previous observational studies have shown
conflicting results. To resolve this uncertainty regarding
FGF23 as a prognostic tool in patients with ESRD, Yang
et al. conducted a systematic review to quantify the associ-
ation between elevated FGF23 and long-term mortality
among ESRD patients. They showed that elevated serum
FGF23 levels were significantly associated with higher risk
of all-cause mortality in ESRD patients, indicating FGF23
predicts poor prognosis in these patients [52]. The
mechanism of the association between elevated serum
FGF23 levels and mortality, however, remained un-
clear. Possible mechanisms may include that FGF23
suppresses vitamin D metabolism, stimulates the renin–
angiotensin– aldosterone system, and increases produc-
tion of inflammatory mediators. In addition, elevated
circulating FGF23 concentration contributes directly to
the high prevalence of LVH in CKD as mentioned above.
These factors have shown a strong association with
adverse outcomes in patients with CKD and ESRD.
FGF23 concentrations had been found to be associated
with serum phosphate level, and FGF23 also leads to
decreased synthesis of vitamin D as mentioned above. The
effects of serum calcium, vitamin D, and PTH on serum
FGF-23 concentration have not been studied. However,
some medical administration including vitamin D supple-
mentation, cinacalcet, and phosphate binders may influ-
ence serum calcium and phosphate level, further affect
FGF23 concentration directly or indirectly [53]. Most of
the included studies had adjusted for serum phosphate
when calculating hazard ratios. However, four studies didnot report medical treatment. Few studies adjusted medi-
cation. The medical treatment with phosphate binders and
vitamin D may potentially be a confounding factor.
Conclusion
CV disease remains frequently complicated in CKD
patients, representing the main cause of death in dialysis
patients, because conventional therapies against athero-
sclerosis, vascular calcification, and CKD-MBD seem to
provide no survival benefit to these patients. Thus, add-
itional research is warranted to improve the under-
standing of vascular aging in CKD. Signaling through
FGF23 and Klotho represents a critical element in the
vascular consequences of CKD-MBD.
Results from clinical and experimental studies support
a consistent, direct, protective effect of Klotho on LVH,
atherosclerosis, and vascular calcification. However,
additional research is needed to elucidate the precise
localization of transmembrane Klotho expression within
the heart and arterial walls, as well as the paracrine and
endocrine effects of secreted Klotho on the vascular sys-
tem. Concomitant reduction of Klotho and FGFR expres-
sion may be responsible for the onset and progression of
(1) CKD-MBD via FGF23 resistance and (2) LVH, ath-
erosclerosis, and vascular calcification resulting from im-
paired endogenous protection against vascular injury.
The classic Klotho-dependent activity of FGF23 on the
kidney and parathyroid glands is accepted as a fundamen-
tal pathway for the maintenance of phosphate homeostasis
and protection against the onset of CKD-MBD. However,
many of the findings are conflicting. For example, experi-
mental data and analysis of families with FGF23 deficiency
confirm that defects in FGF23 signaling induce vascular
damage with eventual critical impact. These data conflict
with observational studies that report a direct association
between high serum FGF23 levels and CV disease, suggest-
ing a role for FGF23 as a biomarker of advanced
CKD-MBD rather than a direct causative agent of vascular
aging. As a second example, experimental data seem to
suggest that LVH results from a direct Klotho-independent
response to high serum FGF23 levels in cardiomyocytes.
Although the direct activity exerted by FGF23 on the arter-
ies is supported by several studies, data regarding whether
this effect is protective or detrimental remain inconsistent.
Future perspectives
Future research in this field will shed light on several
topics, such as Klotho-independent pathways activated
by FGF23, and the precise and dynamic localization of
Klotho-FGFR-FGF23 expression within the heart and
arterial tissue. These studies should be designed to over-
come several weaknesses in the literature, including (i)
lack of information on gender, ethnicity, and genetic
characteristics of human VSMC donors, which may
Nitta Renal Replacement Therapy  (2018) 4:31 Page 7 of 8interact with FGF23 on vascular calcification [54], (ii)
frequent barriers encountered while dealing with transla-
tion from animal to human models and from in vitro to
dynamic in vivo models, (iii) the specific characteristics
and limitations of laboratory methods adopted for asses-
sing Klotho and FGF23 levels, and (iv) the challenging
reproduction and control of systemic conditions, such as
inflammation, which may influence Klotho and FGF23
activity significantly in vivo.
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